Skip to main content
Atrás
HALO logo

Halozyme Therapeutics, Inc.

Calidad de datos: 100%
HALO
NASDAQ Healthcare Biotechnology
$63.24
▲ $1.20 (1.93%)
Cap. Mercado: 7.46B
Rango del Día
$62.69 $63.62
Rango de 52 Semanas
$47.50 $82.22
Volumen
856,291
Promedio 50D / 200D
$71.41 / $66.89
Cierre Anterior
$62.04

Quick Summary

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (631 pares)

Métrica Acción Mediana del Sector
P/E 23.6 0.2
P/B 152.9 3.0
ROE % 153.6 3.6
Net Margin % 22.7 3.8
Rev Growth 5Y % 33.2 10.0
D/E 0.0 0.2

Precio Objetivo de Analistas

Hold
$76.14 +20.4%
Low: $56.00 High: $94.00
P/E Futuro
7.89
EPS Futuro
$8.02
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
1.76B

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $8.61
$8.41 – $8.77
 1.78B 1
FY2029 $9.53
$9.32 – $9.71
 1.92B 1
FY2028 $10.94
$10.71 – $11.17
 2.14B 2

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-17 $2.20 -$0.24 -110.9%
2025-11-03 $1.63 $1.72 +5.5%
2025-08-05 $1.23 $1.54 +25.2%
2025-05-06 $0.95 $1.11 +16.8%
2025-02-18 $1.17 $1.26 +7.7%
2024-10-31 $0.98 $1.27 +29.6%
2024-08-06 $0.76 $0.91 +19.7%
2024-05-07 $0.70 $0.79 +12.9%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Puntos Clave

Revenue grew 33.23% annually over 5 years — strong growth
Earnings declined -28.64% over the past year
ROE of 153.59% indicates high profitability
Net margin of 22.69% shows strong profitability
Debt/Equity of 0.00 — conservative balance sheet
Generating 644.59M in free cash flow

Crecimiento

Revenue Growth (5Y)
33.23%
Revenue (1Y)37.55%
Earnings (1Y)-28.64%
FCF Growth (3Y)31.41%

Calidad

Return on Equity
153.59%
ROIC1254.19%
Net Margin22.69%
Op. Margin58.45%

Seguridad

Debt / Equity
0.00
Current Ratio4.66
Interest Coverage45.03

Valoración

P/E Ratio
23.55
Forward P/E7.89
P/B Ratio152.89
EV/EBITDA8.98
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 37.55% Revenue Growth (3Y) 29.78%
Earnings Growth (1Y) -28.64% Earnings Growth (3Y) 6.08%
Revenue Growth (5Y) 33.23% Earnings Growth (5Y) -5.82%
Profitability
Revenue (TTM) 1.40B Net Income (TTM) 316.89M
ROE 153.59% ROA 12.55%
Gross Margin 78.13% Operating Margin 58.45%
Net Margin 22.69% Free Cash Flow (TTM) 644.59M
ROIC 1254.19% FCF Growth (3Y) 31.41%
Safety
Debt / Equity 0.00 Current Ratio 4.66
Interest Coverage 45.03
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 23.55 Forward P/E 7.89
P/B Ratio 152.89 P/S Ratio 5.34
PEG Ratio -1.04 Forward PEG N/A
EV/EBITDA 8.98 Fwd EV/EBITDA 5.54
Forward P/S 4.25 Fwd Earnings Yield 12.67%
FCF Yield 8.64%
Market Cap 7.46B Enterprise Value 7.33B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.40B 1.02B 829.25M 660.12M 443.31M
Net Income 316.89M 444.09M 281.59M 202.13M 402.71M
EPS (Diluted) 2.56 3.43 2.10 1.44 2.74
Gross Profit 1.09B 855.91M 636.89M 520.81M 361.90M
Operating Income 816.29M 551.48M 337.57M 267.53M 275.90M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2.53B 2.06B 1.73B 1.84B 1.10B
Total Liabilities 2.48B 1.70B 1.65B 1.67B 907.48M
Shareholders' Equity 48.81M 363.82M 83.81M 169.80M 196.95M
Total Debt 0.0 1.51B 1.50B 1.51B 876.67M
Cash & Equivalents 133.82M 115.85M 118.37M 234.20M 118.72M
Current Assets 825.21M 1.09B 746.42M 739.01M 926.29M
Current Liabilities 177.09M 139.10M 112.49M 130.79M 117.15M

Puntuaciones de Estrategias

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#466 of 1049
47
Custom Capital Light Compounder
#69 of 220
49

Actividad Reciente

Entró Cash Flow Compounder
Mar 24, 2026
Entró Capital Light Compounder
Mar 24, 2026